methyl 2-(2-bromoquinolin-4-yl)acetate, 97.0%, 5g

5-butyl-1,3,4-thiadiazol-2-amine, 95.0%, 2.5g

3-Bromo-1-methyl-5-phenyl-1H-pyrazole, 95%, 250mg

Ethyl 3-chloroisonicotinate, 95.0%, 5g

Ethyl 4-(4-aminophenyl)butanoate hydrochloride, 98%, 1g

2-Chloro-3-methoxybenzonitrile, 97%, 5g

Magnetic storage container, for microlitre pipettes 1 pc

6-Bromoquinoline hydrochloride, 95.0%, 25g

Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-, 10mg

N~1~-1-naphthyl-beta-alaninamide hydrochloride, 95.0%, 1g

(3-Aminopiperidin-1-yl)(phenyl)methanone, 98%, 250mg

5-acetamidopyrazolo[1,5-a]pyridine-3-carboxylic acid, 95.0%, 500mg

Formic acid ethyl ester, min. 99%, 1 l, glass packaging